Systemic enzyme therapy in treatment of Reiter's syndrome caused by chlamydia

In spite of the development of a number of methods introduced into clinical practice aimed at increasing the efficacy of pharmacotherapy, none of them fully meets the high requirements of contemporary medical practice. One of the new ways for increasing Reiter's syndrome pharmacotherapy, though practically not investigated so far, could be the new systemic enzyme therapy (SET). Wobenzym, a preparation containing a mixture of plant and animal enzymes, especially developed by the company Mucos Pharm for SET, was used in the research. 56 patients participated in the research. A control group (K II) of 24 patients with Reiter's syndrome caused by chlamydia received standard therapy of Doxycycline per os 100 mg twice daily + Diclofenac for two weeks. The study group (W II) of 32 patients with Reiter's syndrome caused by chlamydia received the above mentioned standard therapy plus Wobenzym tablets three times daily for one month. To clinically assess the efficiency of Wobenzym in the complex therapy of Reiter's syndrome, particular attention was directed to damage to the joints, the characteristic manifestation of this nosologic group. The Ritchie index includes the quantitative intensity index for the following qualitative joint pathology indices: pain in the joints (pain index), pain on palpation (joint index), inflammatory manifestations with synovitis (inflammation index) and functional disturbances (functional index). Each of these indices characterizes the intensity expressed by a gradation degree. Therapeutic efficacy in patients from the study group determined according to the pain index reached 88%, while it was 49% in the control group; determined according to the joint index, 88% in the study group, 53% in the control; determined according to the inflammation index, 98% in the study group, 53% in the control; determined according to the functional index, 79% and 54% respectively. The inclusion of Wobenzym in the therapy of Reiter's syndrome induced by chlamydia increased the efficiency of Reiter's syndrome pharmacotherapy.